Previous 10 | Next 10 |
SAN DIEGO , Dec. 17, 2019 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public offering of 28,125,000 shares of its common stock at $1.60 per sh...
SAN DIEGO , Dec. 16, 2019 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it plans to offer shares of its common stock in an underwritten public offering. In connection with...
Chris penned our third-quarter letter on his first-year anniversary with the GreenWood team. Speed Read: Exor ([[EXOSF]]) exemplifies why “dead money,” is a truism that is never true when skin in the game is involved, as Builders continuously compound value regardless if ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present at the Stifel 2019 He...
MEI Pharma (NASDAQ: MEIP ): Q1 GAAP EPS of -$0.04 beats by $0.13 . More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its first quarter ended September 30, 2019 . "During this past quarter, our primary focus remaine...
When a pharmaceutical company provides a positive update with regards to any of its products, then the stock almost always rises, and that is what has happened with MEIP stock. Positive Development MEI Pharma Inc (NASDAQ:MEIP) provided updated data from the clinical trial of one of...
MEI Pharma (NASDAQ: MEIP ) has risen another 16.7% postmarket after citing updated clinical data from an early-stage trial. More news on: MEI Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
23.78%Change Percent:
MEI Pharma Inc. Company Name:
MEIP Stock Symbol:
NASDAQ Market:
MEI Pharma Inc. Website:
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including ...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...